Astellas Pharma (OTCMKTS:ALPMY) Shares Gap Down – Here’s What Happened

Posted by Linda Flegge on Sep 18th, 2026

Shares of Astellas Pharma Inc. (OTCMKTS:ALPMY – Get Free Report) gapped down before the market opened on Friday . The stock had previously closed at $15.19, but opened at $14.52. Astellas Pharma shares last traded at $15.03, with a volume of 9,093 shares traded.

Analyst Upgrades and Downgrades

Separately, Zacks Research cut Astellas Pharma from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, July 22nd. One analyst has rated the stock with a Strong Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy”.

Read Our Latest Stock Analysis on Astellas Pharma

Astellas Pharma Price Performance

The business’s 50-day simple moving average is $14.32 and its two-hundred day simple moving average is $14.53. The stock has a market cap of $27.24 billion, a price-to-earnings ratio of 11.45 and a beta of 0.08. The company has a debt-to-equity ratio of 0.16, a current ratio of 1.20 and a quick ratio of 0.93.

Astellas Pharma Company Profile

(Get Free Report)

Astellas Pharma Inc is a Japan-based pharmaceutical company that discovers, develops and commercializes prescription medicines for serious and unmet medical needs. Its research and commercial activities focus on areas including oncology, urology, immunology, neuromuscular diseases, ophthalmology and other specialty conditions.

The company’s portfolio includes treatments such as XTANDI for certain prostate cancers, XOSPATA for acute myeloid leukemia, MYRBETRIQ for overactive bladder and VEOZAH for menopausal hot flashes.